Home Patent Forecast® Sectors Log In   Sign Up   Free Trial   Support   Contact   Pricing  
How it works Patent Forecast® Sectors Pricing Insights
Menu

GW Pharmaceuticals Doubles US Epidiolex Sales 2nd Quarter

Z-ARCHIVE-Cannabis Patent Forecast®

August 25, 2019

GW Pharmaceuticals continues to set the bar as they released this month that their US Epidiolex sales more than doubled to $68.4 million in the second quarter from the first, once again sending their stocks soaring during after hours trading. Epidiolex is the first and only FDA approved CBD extract drug used for the treatment of epilepsy. GW Pharma had one US application (2019/0247324) for phytocannabinoid formulations for treating epilepsy published this month. Their US cannabis patent portfolio now has over 180 documents and they have filed several Patent Cooperation Treaties. GW’s portfolio spans all of our tag categories except for processing. Take a closer look at their portfolio with your exclusive access to our interactive and proprietary Patent Forecasting Radian diagram included in your subscription to the Magic Number Cannabis sector.  Your Magic Number subscription will give you the resources you need to make informed decisions regarding the market to help set you ahead of your competitors.

Epilepsy, Seizure, Stroke, Headache

Relevant Patent Documents

Application US20190247324  

Article Source Link

Market Watch


Z-ARCHIVE-Cannabis   Patent Forecast®

View Patent Forecast® Top Corporations News and Insights Data Visualization

For a blog.



301